Tags

Type your tag names separated by a space and hit enter

Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus.
Metabolism 2006; 55(2):232-6M

Abstract

Advanced glycation end products (AGEs) are thought to play a major pathogenic role in diabetic retinopathy. The most important AGE is unknown, but as increased serum methylglyoxal-derived hydroimidazolone has been demonstrated in patients with type 2 diabetes mellitus, the aim of the present study was to elucidate possible associations between serum levels of hydroimidazolone and retinopathy in patients with type 2 diabetes mellitus. We recruited 227 patients with type 2 diabetes mellitus and retinopathy ranging from none to proliferative. Level of retinopathy was determined from 7 standard field stereo photographs per eye according to the Early Treatment Diabetic Retinopathy Study. The patients were 66 +/- 11 years old, with a known diabetes duration of 14 +/- 9 years. Serum levels of hydroimidazolone were determined with a competitive immunoassay. Serum levels of hydroimidazolone were increased in nonproliferative (median, 4.50 U/mL; interquartile range, 3.69-5.77 U/mL) and proliferative retinopathy (median, 4.88 U/mL; interquartile range, 3.70-6.52 U/mL) compared with patients without retinopathy (median, 4.02 U/mL; interquartile range, 3.47-4.88 U/mL) (P = .008 and .002, respectively). There was no association between hydroimidazolone and hemoglobin A1c (r = 0.04, P = .57). In addition, patients with proliferative retinopathy and a relatively short known duration of diabetes, that is, less than the median of 14 years, had increased serum levels of hydroimidazolone (median, 6.91 U/mL; interquartile range, 4.70-8.91 U/mL) compared with those with nonproliferative retinopathy (median, 4.34; interquartile range, 3.86-5.53U/mL, P = .015). Serum levels of hydroimidazolone are increased in type 2 diabetic patients with retinopathy. This association is independent of hitherto known associated factors, such as hemoglobin A1c.

Authors+Show Affiliations

Diabetes Research Centre, Aker and Ullevål University Hospitals, N-0514 Oslo, Norway. dag.fosmark@medisin.uio.no

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16423631

Citation

Fosmark, Dag Sigurd, et al. "Increased Serum Levels of the Specific Advanced Glycation End Product Methylglyoxal-derived Hydroimidazolone Are Associated With Retinopathy in Patients With Type 2 Diabetes Mellitus." Metabolism: Clinical and Experimental, vol. 55, no. 2, 2006, pp. 232-6.
Fosmark DS, Torjesen PA, Kilhovd BK, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metab Clin Exp. 2006;55(2):232-6.
Fosmark, D. S., Torjesen, P. A., Kilhovd, B. K., Berg, T. J., Sandvik, L., Hanssen, K. F., ... Agardh, E. (2006). Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 55(2), pp. 232-6.
Fosmark DS, et al. Increased Serum Levels of the Specific Advanced Glycation End Product Methylglyoxal-derived Hydroimidazolone Are Associated With Retinopathy in Patients With Type 2 Diabetes Mellitus. Metab Clin Exp. 2006;55(2):232-6. PubMed PMID: 16423631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. AU - Fosmark,Dag Sigurd, AU - Torjesen,Peter A, AU - Kilhovd,Bente K, AU - Berg,Tore J, AU - Sandvik,Leiv, AU - Hanssen,Kristian F, AU - Agardh,Carl-David, AU - Agardh,Elisabet, PY - 2005/04/18/received PY - 2005/08/14/accepted PY - 2006/1/21/pubmed PY - 2006/3/18/medline PY - 2006/1/21/entrez SP - 232 EP - 6 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 55 IS - 2 N2 - Advanced glycation end products (AGEs) are thought to play a major pathogenic role in diabetic retinopathy. The most important AGE is unknown, but as increased serum methylglyoxal-derived hydroimidazolone has been demonstrated in patients with type 2 diabetes mellitus, the aim of the present study was to elucidate possible associations between serum levels of hydroimidazolone and retinopathy in patients with type 2 diabetes mellitus. We recruited 227 patients with type 2 diabetes mellitus and retinopathy ranging from none to proliferative. Level of retinopathy was determined from 7 standard field stereo photographs per eye according to the Early Treatment Diabetic Retinopathy Study. The patients were 66 +/- 11 years old, with a known diabetes duration of 14 +/- 9 years. Serum levels of hydroimidazolone were determined with a competitive immunoassay. Serum levels of hydroimidazolone were increased in nonproliferative (median, 4.50 U/mL; interquartile range, 3.69-5.77 U/mL) and proliferative retinopathy (median, 4.88 U/mL; interquartile range, 3.70-6.52 U/mL) compared with patients without retinopathy (median, 4.02 U/mL; interquartile range, 3.47-4.88 U/mL) (P = .008 and .002, respectively). There was no association between hydroimidazolone and hemoglobin A1c (r = 0.04, P = .57). In addition, patients with proliferative retinopathy and a relatively short known duration of diabetes, that is, less than the median of 14 years, had increased serum levels of hydroimidazolone (median, 6.91 U/mL; interquartile range, 4.70-8.91 U/mL) compared with those with nonproliferative retinopathy (median, 4.34; interquartile range, 3.86-5.53U/mL, P = .015). Serum levels of hydroimidazolone are increased in type 2 diabetic patients with retinopathy. This association is independent of hitherto known associated factors, such as hemoglobin A1c. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/16423631/Increased_serum_levels_of_the_specific_advanced_glycation_end_product_methylglyoxal_derived_hydroimidazolone_are_associated_with_retinopathy_in_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(05)00340-9 DB - PRIME DP - Unbound Medicine ER -